アルギナートオリゴサッカライドは,腸内微生物群を調節するのではなく,茶色の脂肪の発熱を促進することによって,肥満を予防し,治療する
Yuncong Xu1, Jun Jiang1, Tao Li2
1Key Laboratory of Food Bioengineering (China National Light Industry), College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China.
Journal of advanced research
|September 3, 2025
まとめ
アルギナートオリゴサッカライド (AOS) は,炎症と酸化ストレスを軽減し,茶色脂肪組織のエネルギー消費を増加させることで,肥満を効果的に予防し,治療します. 利点は腸内微生物群の調節とは無関係です
科学分野:
- 生物化学
- 代謝 健康
- 栄養学
背景:
- 機能性オリゴサッカライドは,複数のメカニズムを通じて生理学的利点を提供します.
- アルギナートオリゴサッカライド (AOS) が肥満を改善する特定のメカニズムはよく理解されていません.
研究 の 目的:
- マウスモデルでのAOS (DP2-4) の抗肥満効果を評価する.
- AOSの治療作用の根本的なメカニズムの解明
主な方法:
- 肥満の予防と治療モデル
- 腸内微生物の役割を評価するための抗生物質の介入
- 内注射で直接的な治療効果を調べる
主要な成果:
- AOSs (1,000 mg/ kg) は,オルリスタットと同様の肥満の予防と治療効果を示した.
- AOSは代謝プロフィールを逆転させ,腸内脂質吸収を減少させ,肝臓の脂質代謝を改善した.
- AOSは炎症,酸化ストレス,エネルギー消費の増加,ブラウン脂肪組織ミトコンドリア機能を改善しました.
結論:
- AOSは炎症と酸化ストレスを軽減することによって肥満を予防し,治療します.
- 茶色脂肪組織のエネルギー消費の増加は,AOSの抗肥満効果の重要なメカニズムです.
- 肥満に対するAOSの治療効果は主に腸内微生物群によって媒介されるものではありません.
関連する概念動画
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Obesity
609
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
609
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252


